Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | CART19-BE-01: ARI-0001 in CD19+ malignancies

Valentín Ortiz-Maldonado • 11 Oct 2020
Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Leukemia Lymphoma Non-Hodgkin Lymphoma ARI-0001 CAR-T
CART19-BE-01

Valentín Ortiz-Maldonado, MD, of the Hospital Clinic, Barcelona, Spain, discusses the initial results of the CART19-BE-01 (NCT03144583), a Phase I multicenter study evaluating ARI-0001, a CD19 targeting chimeric antigen receptor T-cell, in patients with CD19+ relapsed/refractory hematological malignancies. The primary and secondary endpoints of safety and efficacy were met, with an overall survival of 68.6% at one year. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Valentín Ortiz-Maldonado

3:11
ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease
Valentín Ortiz-Maldonado • 3 Feb 2021
1:12
ARI-0001 in CD19+ malignancies: next steps
Valentín Ortiz-Maldonado • 3 Feb 2021
1:45
Challenges associated with CAR T-cell production
Valentín Ortiz-Maldonado • 1 Sep 2020
3:35
Sinusoidal obstruction syndrome in patients with R/R B-cell ALL
Valentín Ortiz-Maldonado • 1 Sep 2020

Related Videos

5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
3:52
Outcomes of children and young adults with B-ALL following tisa-cel reinfusion
Kevin McNerney • 24 Feb 2023
3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL
Nirav Shah • 15 Feb 2023
3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
The content of VJRegenMed is intended for healthcare professionals